Want to see HK:1875 full AI Analyst Report?
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$5.87
Previous CloseN/A
Volume400.00
Average Volume (3M)712.12K
Market Cap
HK$2.95B
Enterprise ValueHK$2.48K
Total Cash (Recent Filing)HK$263.69M
Total Debt (Recent Filing)HK$350.93M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding772,787,900
10 Day Avg. Volume378,440
30 Day Avg. Volume712,120
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$566.10M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageManageable leverage and substantial equity relative to assets provide a reasonably stable financial base for continued drug development. This reduces balance-sheet pressure compared with highly indebted peers and preserves flexibility to fund operations or absorb periods of earnings volatility.
Positive Operating Cash FlowOperating cash flow has remained positive through 2025, showing that the business has generated cash from operations even as performance weakened. That underlying cash conversion is a constructive foundation, although its recent decline indicates the durability of this support must be monitored.
Prior Revenue ExpansionStrong revenue expansion from 2021 through 2024 demonstrates that the company has previously been able to grow its oncology-focused biopharmaceutical business. This track record supports the possibility of rebuilding scale if product demand and commercialization execution recover.
Bears Say
Sharp Revenue DeclineThe sharp 2025 revenue contraction indicates a material reversal in commercial momentum after several years of expansion. A sustained decline would reduce operating scale, weaken the funding base for oncology development, and make future revenue recovery more dependent on successful execution.
Return To LossesReturning to meaningful losses after a profitable 2024 highlights volatile earnings power and weak near-term profitability durability. Negative operating and net margins can constrain internally funded investment, increase dependence on financing, and make results more sensitive to revenue fluctuations.
Persistent Negative Free Cash FlowPersistent negative free cash flow shows that operating cash generation has not covered ongoing investment and other cash requirements over the reported period. Continued cash deficits could limit strategic flexibility and require external funding while the company develops and commercializes medicines.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$5.87 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$2.95B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Mar 25, 2027 which is in 184 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Aug 21, 2026. The company reported -HK$0.093 earnings per share for the quarter.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Overvalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of -HK$0.093 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Technical Analysis
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―